Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2018

17.09.2018 | Maternal-Fetal Medicine

A prospective cohort study on the prediction of the diagnosis-to-delivery time in preeclamptic pregnancies: should the sFlt-1/PlGF ratio be added to routine evaluations?

verfasst von: Semir Kose, Gamze Tuna, Gülnar Nuriyeva, Sabahattin Altunyurt, Gül Hüray Islekel, Omer Erbil Doğan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To analyze the clinical and laboratory factors that potentially affect the diagnosis-to-delivery time in preeclamptic pregnancies.

Methods

In this cross-sectional study, we followed 24 early onset preeclampsia (E-PE) and 26 late-onset preeclampsia (L-PE) cases. Maternal serum samples were obtained at the time of diagnosis and stored at − 80 °C until ELISA analysis for soluble fms-like tyrosine kinase-1 (SFlt-1) and placental growth factor (PlGF) levels.

Results

The median follow-up duration was 68 (1–339) h in the E-PE group and 330 (7–1344) h in the L-PE group. Maternal mean arterial pressure (MAP) at hospitalization was the strongest variable, and the sFlt-1/PlGF ratio added significantly to the Cox regression model. In the E-PE cases, the median sFlt-1/PlGF ratio was significantly higher in the subgroup with a follow-up duration > 48 h than in the subgroup of cases with a follow-up duration ≤ 48 h (5109 vs. 2080; p = 0.038), and none of the seven cases with an sFlt-1/PlGF ratio ≥ 75th percentile delivered during the first 48 h. Neither the 24-h proteinuria nor the gestational age at diagnosis added to the predictive power of the MAP at hospitalization.

Conclusion

Incorporation of the sFlt-1/PlGF ratio to the routine evaluation of preeclamptic pregnancies may help in the prediction of progression and management planning.
Literatur
1.
2.
Zurück zum Zitat Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R (2014) Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 10:531–540CrossRefPubMedCentral Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R (2014) Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 10:531–540CrossRefPubMedCentral
3.
Zurück zum Zitat American College of Obstetricians and Gynecologists’ (ACOG) (2013) American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy: hypertension in pregnancy. Obstet Gynecol 122:1122–1131CrossRef American College of Obstetricians and Gynecologists’ (ACOG) (2013) American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy: hypertension in pregnancy. Obstet Gynecol 122:1122–1131CrossRef
5.
Zurück zum Zitat Churchill D, Duley L, Thornton JG, Jones L (2013) Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev 7:CD003106 Churchill D, Duley L, Thornton JG, Jones L (2013) Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev 7:CD003106
6.
Zurück zum Zitat Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM (2011) Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 205:191–198CrossRef Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM (2011) Evaluation and management of severe preeclampsia before 34 weeks’ gestation. Am J Obstet Gynecol 205:191–198CrossRef
7.
Zurück zum Zitat Wang Y, Hao M, Sampson S, Xia J (2017) Elective delivery versus expectant management for pre-eclampsia: a meta-analysis of RCTs. Arch Gynecol Obstet 295:607–622CrossRefPubMedCentral Wang Y, Hao M, Sampson S, Xia J (2017) Elective delivery versus expectant management for pre-eclampsia: a meta-analysis of RCTs. Arch Gynecol Obstet 295:607–622CrossRefPubMedCentral
8.
Zurück zum Zitat Redman CW, Sargent IL, Staff AC (2014) IFPA senior award lecture: making sense of pre-eclampsia- two placental causes of preeclampsia? Placenta 35:S20–S25CrossRefPubMedCentral Redman CW, Sargent IL, Staff AC (2014) IFPA senior award lecture: making sense of pre-eclampsia- two placental causes of preeclampsia? Placenta 35:S20–S25CrossRefPubMedCentral
9.
Zurück zum Zitat Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911–919CrossRefPubMedCentral Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA (2012) Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911–919CrossRefPubMedCentral
10.
Zurück zum Zitat ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77:67–75CrossRef ACOG Committee on Obstetric Practice (2002) ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77:67–75CrossRef
11.
Zurück zum Zitat Locatelli A, Zagarella A, Toso L, Assi F, Ghidini A, Biffi A (2004) Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med 15:233–236CrossRefPubMedCentral Locatelli A, Zagarella A, Toso L, Assi F, Ghidini A, Biffi A (2004) Serial assessment of amniotic fluid index in uncomplicated term pregnancies: prognostic value of amniotic fluid reduction. J Matern Fetal Neonatal Med 15:233–236CrossRefPubMedCentral
12.
Zurück zum Zitat Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292:507–518CrossRefPubMedCentral Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H (2015) Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet 292:507–518CrossRefPubMedCentral
13.
Zurück zum Zitat Bahlmann F, Al Naimi A (2016) Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia. Arch Gynecol Obstet 294:1133–1139CrossRefPubMedCentral Bahlmann F, Al Naimi A (2016) Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia. Arch Gynecol Obstet 294:1133–1139CrossRefPubMedCentral
14.
Zurück zum Zitat Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A (2014) Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol 43:525–532CrossRefPubMedCentral Gómez-Arriaga PI, Herraiz I, López-Jiménez EA, Escribano D, Denk B, Galindo A (2014) Uterine artery Doppler and sFlt-1/PlGF ratio: prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol 43:525–532CrossRefPubMedCentral
15.
Zurück zum Zitat Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206:58.e1–58.e8CrossRef Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H (2012) The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 206:58.e1–58.e8CrossRef
16.
Zurück zum Zitat McKinney D, Boyd H, Langager A, Oswald M, Pfister A, Warshak CR (2016) The impact of fetal growth restriction on latency in the setting of expectant management of preeclampsia. Am J Obstet Gynecol 214:395.e1–395.e7CrossRef McKinney D, Boyd H, Langager A, Oswald M, Pfister A, Warshak CR (2016) The impact of fetal growth restriction on latency in the setting of expectant management of preeclampsia. Am J Obstet Gynecol 214:395.e1–395.e7CrossRef
17.
Zurück zum Zitat Chen Q, Shen F, Gao YF, Zhao M (2015) An analysis of expectant management in women with early-onset preeclampsia in China. J Hum Hypertens 29:379–384CrossRefPubMedCentral Chen Q, Shen F, Gao YF, Zhao M (2015) An analysis of expectant management in women with early-onset preeclampsia in China. J Hum Hypertens 29:379–384CrossRefPubMedCentral
18.
Zurück zum Zitat Zhao M, Zhu Z, Liu C, Zhang Z (2017) Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet 295:1079–1087CrossRefPubMedCentral Zhao M, Zhu Z, Liu C, Zhang Z (2017) Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: a systematic review and meta-analysis. Arch Gynecol Obstet 295:1079–1087CrossRefPubMedCentral
19.
Zurück zum Zitat Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658CrossRefPubMedCentral Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649–658CrossRefPubMedCentral
20.
Zurück zum Zitat Mooney SS, Lee RM, Tong S, Brownfoot FC (2016) Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. J Matern Fetal Neonatal Med 29:3821–3826CrossRefPubMedCentral Mooney SS, Lee RM, Tong S, Brownfoot FC (2016) Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. J Matern Fetal Neonatal Med 29:3821–3826CrossRefPubMedCentral
21.
Zurück zum Zitat Pilliod RA, Feinberg BB, Burwick RM (2016) Maternal and feto-placental phenotypes of early-onset severe preeclampsia. J Matern Fetal Neonatal Med 29:1209–1213CrossRefPubMedCentral Pilliod RA, Feinberg BB, Burwick RM (2016) Maternal and feto-placental phenotypes of early-onset severe preeclampsia. J Matern Fetal Neonatal Med 29:1209–1213CrossRefPubMedCentral
22.
Zurück zum Zitat Onda K, Tong S, Nakahara A, Kondo M, Monchusho H, Hirano T, Kaitu’u-Lino T, Beard S, Binder N, Tuohey L, Brownfoot F, Hannan NJ (2015) Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction:potential therapeutic for preeclampsia. Hypertension 65:855–862CrossRefPubMedCentral Onda K, Tong S, Nakahara A, Kondo M, Monchusho H, Hirano T, Kaitu’u-Lino T, Beard S, Binder N, Tuohey L, Brownfoot F, Hannan NJ (2015) Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction:potential therapeutic for preeclampsia. Hypertension 65:855–862CrossRefPubMedCentral
23.
Zurück zum Zitat Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Tuohey L, Kaitu’u-Lino TJ (2015) YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: a possible therapeutic for preeclampsia. Mol Cell Endocrinol 413:202–208CrossRefPubMedCentral Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Tuohey L, Kaitu’u-Lino TJ (2015) YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: a possible therapeutic for preeclampsia. Mol Cell Endocrinol 413:202–208CrossRefPubMedCentral
24.
Zurück zum Zitat Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu’u-Lino TJ, Tong S (2016) Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 214:356.e1–356.e15CrossRef Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu’u-Lino TJ, Tong S (2016) Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 214:356.e1–356.e15CrossRef
Metadaten
Titel
A prospective cohort study on the prediction of the diagnosis-to-delivery time in preeclamptic pregnancies: should the sFlt-1/PlGF ratio be added to routine evaluations?
verfasst von
Semir Kose
Gamze Tuna
Gülnar Nuriyeva
Sabahattin Altunyurt
Gül Hüray Islekel
Omer Erbil Doğan
Publikationsdatum
17.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2018
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-018-4903-5

Weitere Artikel der Ausgabe 5/2018

Archives of Gynecology and Obstetrics 5/2018 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.